These studies are designed to develop improved methods for detecting and treating malignancies. Our group performs preclinical evaluation of antibodies that appear to be promising after initial screening by various laboratories at the National Cancer Institute and develops these antibodies for clinical application. The clinical trials evaluating their pharmacokinetics and dosimetry are performed by our group. A collaborative radioimmunotherapy trial with Dr. Waldmann (PI), in which we used humanized anti-tac monoclonal antibody, is ongoing. Various protocols using [F-18] FDG in PET and [O-15] water for tumor detection, followup, and blood flow measurements are ongoing. We have begun preclinical studies evaluating pretargeting of antibodies for tumor therapy and have demonstrated therapeutic responses with Y-90 and Bi-213.

Agency
National Institute of Health (NIH)
Institute
Clinical Center (CLC)
Type
Intramural Research (Z01)
Project #
1Z01CL000600-07
Application #
6431793
Study Section
(NMRR)
Project Start
Project End
Budget Start
Budget End
Support Year
7
Fiscal Year
2000
Total Cost
Indirect Cost
Name
Clinical Center
Department
Type
DUNS #
City
State
Country
United States
Zip Code